September 2013. Volume 9. Number 3

Involvement of respiratory syncytial virus in infant recurring bronchitis and possible prevention

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

CA | Associated comment

Author: Moral Gil L1.
1Unidad de Neumología y Alergología Pediátrica. Hospital General Universitario de Alicante. Alicante. España.
Correspondence: Luis Moral Gil. Email: lmoralg@gmail.com
Publication date: 04/09/2013

Key words: infant; bronchitis

How to cite this article

Moral Gil L. Implicación del virus respiratorio sincitial en las bronquitis recurrentes del lactante y su posible prevención. Evid Pediatr. 2013;9:52.

CA | Associated comment

Author: Moral Gil L1.
1Unidad de Neumología y Alergología Pediátrica. Hospital General Universitario de Alicante. Alicante. España.
Correspondence: Luis Moral Gil. Email: lmoralg@gmail.com
Key words: infant; bronchitis
Publication date: 04/09/2013

How to cite this article

Moral Gil L. Implicación del virus respiratorio sincitial en las bronquitis recurrentes del lactante y su posible prevención. Evid Pediatr. 2013;9:52.

References


  1. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375:1545-55.
  2. Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, et al; Dutch RSV Neonatal Network. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. NEJM. 2013;368:1791-9.
  3. Ochoa Sangrador C, González de Dios J. Palivizumab podría reducir los episodios de sibilantes en prematuros tardíos, aunque no está clara su repercusión clínica. Evid Pediatr. 2013;9:42.
  4. Blanken M, Rovers M, Sanders D, Bont L. Ethical considerations and rationale of the MAKI trial: a multicenter double-bind randomized placebo-controlled trial into the preventive effect of palivizumab on recurrent wheezing associated with respiratory syncytial virus infection in children with a gestational age of 33-35 weeks. Contemp Clin Trials. 2012;33:1287-92.
  5. Nair H, Verma VR, Theodoratou E. An evaluation of the emerging interventions against Respiratory Syncytial Virus (RSV)-associated acute lower respiratory infections in children. BMC Public Health. 2011;11(Suppl 3:S30).

Related Articles

AVC | More than six doses of palivizumab are needed to prevent one episode of wheezing in late preterm infants

Ochoa Sangrador C, González de Dios J. Para evitar un episodio de sibilancias en prematuros tardíos se requieren más de seis dosis de palivizumab. Evid Pediatr. 2013;9:42.
04/09/2013

Linked Comment